Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381965 | 0.79 | ALDH1A1 (0.41) | PTGDR2CCR5RBP4MAPK1LMNA | |
| SCHEMBL20909917 | 0.77 | ALDH1A1 (0.41) | POLBCA2LMNAALDH1A1GAA | |
| SCHEMBL24848636 | 0.77 | CYP1A2 (0.41) | CA2LMNAALDH1A1GAAKMT2A | |
| SCHEMBL12401762 | 0.75 | GAA (0.52) | RBP4POLBMAPK1LMNAALDH1A1 | |
| SCHEMBL30874683 | 0.75 | PTGDR2 (0.46) | PTGDR2RBP4POLBMAPK1CA2 | |
| SCHEMBL9248443 | 0.75 | PTGDR2 (0.46) | PTGDR2RBP4POLBMAPK1CA2 | |
| SCHEMBL24094415 | 0.74 | HRH4 (0.33) | CCR5HRH4 | |
| SCHEMBL9566865 | 0.73 | ALOX15 (0.42) | CCR5POLBMAPK1LMNAALDH1A1 | |
| SCHEMBL30645676 | 0.73 | PTGDR2 (0.44) | PTGDR2RBP4MAPK1CA2LMNA | |
| SCHEMBL7178861 | 0.73 | PTGDR2 (0.44) | PTGDR2RBP4MAPK1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| US-11299493-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3694861-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-8163952-B2 | RAR receptor agonist ligands and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2146951-B1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100261754-A1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299493-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, NME1 | PTGDR2 1956/4885CCR5 3708/4885RBP4 4765/4885 |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | PTGDR2 1956/4885CCR5 3708/4885RBP4 4765/4885 |
| US-20100261754-A1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | RARA, RARB, RARG | PTGDR2 205/4885CCR5 419/4885RBP4 99/4885 |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | PTGDR2 1956/4885CCR5 3708/4885RBP4 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.